Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Pfizer (NYSE:PFE) announced three deals on Monday covering compounds for HCV and schizophrenia and a genomic test for renal cell carcinoma. Pfizer
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury